BiomeSense is at the forefront of microbiome research, utilizing advanced technologies to facilitate personalized medicine through the analysis of gut microbiome data. Their flagship technology, GutLab, enables continuous tracking of a patient's gut microbiome, allowing for real-time data generation throughout treatment journeys. This technology is designed for ease of use and maintenance, significantly reducing costs and increasing data output. By sequencing samples and correlating them with clinical data, GutLab creates high-resolution maps of the microbiome, revealing critical insights into natural variations and treatment effects.

Complementing GutLab is the MetaBiome platform, which employs AI-driven bioinformatics to analyze the extensive microbiome data generated. This platform utilizes both established and innovative time-series analyses to identify clinically relevant shifts and patterns, unlocking previously inaccessible host-microbiome interactions. Together, these technologies not only enhance the understanding of the microbiome's role in health and disease but also support the discovery of novel biomarkers and the development of therapeutics, diagnostics, and probiotics tailored to individual health needs.

United States

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

BiomeSense

Company Details